CM Connell, SEM Raby, I Beh, TR Flint, EH Williams, DT Fearon, DI Jodrell, T Janowitz
Journal name: 
Citation info: 
Immune-related radiological and biomarker monitoring in cancer immunotherapy trials permits interrogation of efficacy and reasons for therapeutic failure. We report the results from a cross-sectional analysis of response monitoring in 685 T-cell checkpoint-targeted cancer immunotherapy trials in solid malignancies, as registered on the U.S. National Institutes of Health trial registry by October 2016. Immune-related radiological response criteria were registered for only 25% of clinical trials. Only 38% of trials registered an exploratory immunological biomarker, and registration of immunological biomarkers has decreased over the last 15 years. We suggest that increasing the utilization of immune-related response monitoring across cancer immunotherapy trials will improve analysis of outcomes and facilitate translational efforts to extend the benefit of immunotherapy to a greater proportion of patients with cancer.
Research group: 
Jodrell Group
E-pub date: 
31 Jan 2018
Users with this publication listed: 
Claire Connell
Duncan Jodrell
Edward Williams
Thomas Flint
Tobias Janowitz